Quality of life and societal costs in patients with dilated cardiomyopathy.

IF 5.4 3区材料科学 Q2 CHEMISTRY, PHYSICAL

ACS Applied Energy Materials Pub Date : 2024-06-20 DOI:10.1093/ehjqcco/qcad056

Isabell Wiethoff, Maurits Sikking, Silvia Evers, Andrea Gabrio, Michiel Henkens, Michelle Michels, Job Verdonschot, Stephane Heymans, Mickaël Hiligsmann

{"title":"Quality of life and societal costs in patients with dilated cardiomyopathy.","authors":"Isabell Wiethoff, Maurits Sikking, Silvia Evers, Andrea Gabrio, Michiel Henkens, Michelle Michels, Job Verdonschot, Stephane Heymans, Mickaël Hiligsmann","doi":"10.1093/ehjqcco/qcad056","DOIUrl":null,"url":null,"abstract":"Aims: Dilated cardiomyopathy (DCM) is a major cause of heart failure impairing patient wellbeing and imposing a substantial economic burden on society, but respective data are missing. This study aims to measure the quality of life (QoL) and societal costs of DCM patients.Methods and results: A cross-sectional evaluation of QoL and societal costs of DCM patients was performed through the 5-level EuroQol and the Medical Consumption Questionnaire and Productivity Cost Questionnaire, respectively. QoL was translated into numerical values (i.e. utilities). Costs were measured from a Dutch societal perspective. Final costs were extrapolated to 1 year, reported in 2022 Euros, and compared between DCM severity according to NYHA classes. A total of 550 DCM patients from the Maastricht cardiomyopathy registry were included. Mean age was 61 years, and 34% were women. Overall utility was slightly lower for DCM patients than the population mean (0.840 vs. 0.869, P = 0.225). Among EQ-5D dimensions, DCM patients scored lowest in 'usual activities'. Total societal DCM costs were €14 843 per patient per year. Cost drivers were productivity losses (€7037) and medical costs (€4621). Patients with more symptomatic DCM (i.e. NYHA class III or IV) had significantly higher average DCM costs per year compared to less symptomatic DCM (€31 099 vs. €11 446, P < 0.001) and significantly lower utilities (0.631 vs. 0.883, P < 0.001).Conclusion: DCM is associated with high societal costs and reduced QoL, in particular with high DCM severity.","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":null,"pages":null},"PeriodicalIF":5.4000,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11187720/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Energy Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ehjqcco/qcad056","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: Dilated cardiomyopathy (DCM) is a major cause of heart failure impairing patient wellbeing and imposing a substantial economic burden on society, but respective data are missing. This study aims to measure the quality of life (QoL) and societal costs of DCM patients.

Methods and results: A cross-sectional evaluation of QoL and societal costs of DCM patients was performed through the 5-level EuroQol and the Medical Consumption Questionnaire and Productivity Cost Questionnaire, respectively. QoL was translated into numerical values (i.e. utilities). Costs were measured from a Dutch societal perspective. Final costs were extrapolated to 1 year, reported in 2022 Euros, and compared between DCM severity according to NYHA classes. A total of 550 DCM patients from the Maastricht cardiomyopathy registry were included. Mean age was 61 years, and 34% were women. Overall utility was slightly lower for DCM patients than the population mean (0.840 vs. 0.869, P = 0.225). Among EQ-5D dimensions, DCM patients scored lowest in 'usual activities'. Total societal DCM costs were €14 843 per patient per year. Cost drivers were productivity losses (€7037) and medical costs (€4621). Patients with more symptomatic DCM (i.e. NYHA class III or IV) had significantly higher average DCM costs per year compared to less symptomatic DCM (€31 099 vs. €11 446, P < 0.001) and significantly lower utilities (0.631 vs. 0.883, P < 0.001).

Conclusion: DCM is associated with high societal costs and reduced QoL, in particular with high DCM severity.

查看原文本刊更多论文

扩张型心肌病患者的生活质量和社会成本。

目的：扩张型心肌病（DCM）是导致心力衰竭的主要原因之一，它损害了患者的健康，并给社会造成了巨大的经济负担，但目前尚缺乏相关数据。本研究旨在测量 DCM 患者的生活质量（QoL）和社会成本：通过 5 级 EuroQol 以及医疗消耗问卷和生产力成本问卷，分别对 DCM 患者的生活质量和社会成本进行了横向评估。QoL 转化为数值（即效用）。成本从荷兰社会角度进行衡量。最终成本推算至 1 年，以 2022 欧元为单位进行报告，并根据 NYHA 分级对 DCM 严重程度进行比较。马斯特里赫特心肌病登记处共纳入了 550 名 DCM 患者。平均年龄为 61 岁，34% 为女性。DCM 患者的总体效用略低于人口平均值（0.840 vs. 0.869，P = 0.225）。在 EQ-5D 维度中，DCM 患者在 "日常活动 "方面得分最低。每位 DCM 患者每年的社会总成本为 14 843 欧元。成本驱动因素是生产力损失（7037 欧元）和医疗成本（4621 欧元）。与症状较轻的 DCM 患者相比，症状较重的 DCM 患者（即 NYHA III 级或 IV 级）每年的平均 DCM 费用明显较高（31 099 欧元对 11 446 欧元，P < 0.001），而效用则明显较低（0.631 对 0.883，P < 0.001）：结论：DCM 与高昂的社会成本和生活质量下降有关，尤其是在 DCM 严重程度较高的情况下。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Energy Materials Materials Science-Materials Chemistry

CiteScore

10.30

自引率

6.20%

发文量

1368

期刊介绍： ACS Applied Energy Materials is an interdisciplinary journal publishing original research covering all aspects of materials, engineering, chemistry, physics and biology relevant to energy conversion and storage. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrate knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important energy applications.